[{"data":1,"prerenderedAt":252},["ShallowReactive",2],{"$f3c7p4o5a7ov8w":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":54,"top_diseases":83,"top_companies":117,"key_results":146,"trends":239,"previous_editions":248,"comparison":159,"highlighted_classes":249},1,"aacr-2026","AACR","aacr","AACR Annual Meeting 2026",2026,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},7579,2852,880,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 2\u002F3":20,"Phase 3":21},225,92,112,3,36,[23,27,30,33,36,39,43,46,49,52],{"name":24,"count":25,"share":26},"PDCD1",110,4,{"name":28,"count":29,"share":26},"TUBB",106,{"name":31,"count":32,"share":26},"EGFR",103,{"name":34,"count":35,"share":20},"ERBB2",99,{"name":37,"count":38,"share":20},"CD3",93,{"name":40,"count":41,"share":42},"CD274",71,2,{"name":44,"count":45,"share":42},"TOP1",64,{"name":47,"count":48,"share":4},"HRAS",41,{"name":50,"count":51,"share":4},"CD19",40,{"name":53,"count":51,"share":4},"TACSTD2",[55,59,63,66,70,74,77,80],{"name":56,"count":57,"share":58},"Small molecules",1691,59,{"name":60,"count":61,"share":62},"Antibody-drug conjugates",353,12,{"name":64,"count":65,"share":62},"Monoclonal antibodies",343,{"name":67,"count":68,"share":69},"Bispecific antibodies",239,8,{"name":71,"count":72,"share":73},"Cell therapies",171,6,{"name":75,"count":76,"share":26},"Non-antibody therapeutic proteins",102,{"name":78,"count":79,"share":20},"Peptides",96,{"name":81,"count":82,"share":20},"Oligonucleotide and RNA therapeutics",85,[84,87,91,94,98,101,104,107,111,114],{"name":85,"count":86,"share":62},"breast cancer",331,{"name":88,"count":89,"share":90},"non-small cell lung cancer (NSCLC)",313,11,{"name":92,"count":93,"share":90},"colorectal cancer (CRC)",303,{"name":95,"count":96,"share":97},"triple-negative breast cancer (TNBC)",197,7,{"name":99,"count":100,"share":97},"pancreatic adenocarcinoma (PDAC)",186,{"name":102,"count":103,"share":73},"pancreatic cancer (PC)",177,{"name":105,"count":106,"share":73},"ovarian cancer",163,{"name":108,"count":109,"share":110},"glioblastoma (GBM)",144,5,{"name":112,"count":113,"share":110},"gastric cancer (GC)",138,{"name":115,"count":116,"share":110},"prostate cancer (PCa)",136,[118,121,124,126,129,132,135,138,140,143],{"name":119,"count":120,"share":20},"AstraZeneca",97,{"name":122,"count":123,"share":20},"Bristol Myers Squibb",81,{"name":125,"count":45,"share":42},"Merck",{"name":127,"count":128,"share":42},"Pfizer",63,{"name":130,"count":131,"share":42},"Novartis",53,{"name":133,"count":134,"share":42},"Genentech",49,{"name":136,"count":137,"share":42},"Daiichi Sankyo",48,{"name":139,"count":137,"share":42},"GSK",{"name":141,"count":142,"share":4},"Eli Lilly",33,{"name":144,"count":145,"share":4},"REVOLUTION Medicines",32,[147,155,162,169,177,186,193,199,207,216,222,232],{"title":148,"drug":149,"company":151,"phase":152,"disease":88,"finding":153,"url":154},"Dirozalkib versus crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Results from the multicenter, randomized, open-label phase 3 trial",{"name":150,"slug":150},"dirozalkib","Xuanzhu Biopharmaceutical","Phase 3","The INV-assessed median PFS (mPFS) was significantly longer in the dirozalkib group than in the crizotinib group (29.50 mo [95%CI: 20.30-not reached] vs. 12.94 mo [11.07-17.61]; hazard ratio [HR] = 0.474, P \u003C 0.0001).","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct299",{"title":156,"drug":157,"company":125,"phase":152,"disease":88,"finding":160,"url":161},"Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)",{"name":158,"slug":159},"pembrolizumab + ramucirumab",null,"In SCC, the HR (95% CI) was 0.90 [0.66-1.22] p= 0.25 with mOS of 10.7 mos for RP and 9.6 mos with SOC.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct140",{"title":163,"drug":164,"company":159,"phase":152,"disease":166,"finding":167,"url":168},"Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial",{"name":165,"slug":165},"tebentafusp","uveal melanoma (UM)","With extended follow-up, the OS continued to favor tebentafusp, with a stratified hazard ratio of 0.67 (95% CI, 0.54-0.85).","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct029",{"title":170,"drug":171,"company":159,"phase":173,"disease":174,"finding":175,"url":176},"Enhanced monocyte activation and T cell cytotoxicity underlie the benefit of neoadjuvant durvalumab plus gemcitabine-cisplatin (D+GP) in localized biliary tract cancer (BTC): Phase 2 DEBATE study",{"name":172,"slug":172},"durvalumab","Phase 2","biliary cancer","In the D+GP group, the objective response rate was 38.7%, median PFS 19 months (1-sided 80% CI, 15-21), and OS 28 months (24-43), versus 14.3%, 6 months (3-11), and 30 months (23-44) in the GP group.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-6454",{"title":178,"drug":179,"company":182,"phase":183,"disease":88,"finding":184,"url":185},"SHR-A1811 ± adebrelimab as first-line (1L) treatment for advanced HER2-mutant NSCLC: A randomized phase 2 cohort from a phase 1b\u002F2 study",{"name":180,"slug":181},"trastuzumab rezetecan","trastuzumab-rezetecan","Hengrui Therapeutics","Phase 1\u002F2","PFS events occurred in 10 pts (27.8%) with combo vs 13 (40.6%) with SHR-A1811; median PFS was NR (95% CI 15.3-NR) vs 17.9 mo (95% CI 9.7-NR; HR 0.65, 95% CI 0.28-1.47).","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct301",{"title":187,"drug":188,"company":159,"phase":183,"disease":190,"finding":191,"url":192},"Results from the phase 1b\u002F2 Morpheus liver study in patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC): Muzastotug (ADG126: masked anti-CTLA-4 Ab) combination arm",{"name":189,"slug":189},"muzastotug","hepatocellular carcinoma (HCC)","Serious AEs occurred in 33% of cases for the ADG126 arm compared to 55% for control.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct054",{"title":194,"drug":195,"company":159,"phase":183,"disease":92,"finding":197,"url":198},"Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1\u002F2 study",{"name":196,"slug":196},"elisrasib","In combo CRC arm, 31\u002F31 (100%) pts had any grade TRAEs, 15\u002F31 (48.4%, including 19.4% related to elisrasib) pts had G3 TRAEs.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct303",{"title":200,"drug":201,"company":159,"phase":183,"disease":204,"finding":205,"url":206},"First-Line mRNA-4359 plus pembrolizumab (pembro) in locally advanced or metastatic melanoma: Results from the phase 1\u002F2 mRNA-4359-P101 study",{"name":202,"slug":203},"mRNA-4359","mrna-4359","melanoma","mRNA-4359-related TEAEs occurred in 11 pts (92%; all grade 1\u002F2); the most common TEAE was injection site pain (67%).","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct106",{"title":208,"drug":209,"company":159,"phase":183,"disease":213,"finding":214,"url":215},"Preliminary results from the phase 1b\u002F2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors",{"name":210,"slug":211,"named_as":212},"zocilurtatug pelitecan","zocilurtatug-pelitecan","ZL-1310","neuroendocrine carcinoma (NEC)","One pt (3.6%) decreased the dose of ZL-1310 due to AE (G3 neutrophil count decreased); one pt (3.6%) experienced G2 interstitial lung disease leading to treatment discontinuation.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct189",{"title":217,"drug":218,"company":159,"phase":183,"disease":102,"finding":220,"url":221},"Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis",{"name":219,"slug":219},"narmafotinib","Most common AEs related to narmafotinib were nausea (29%), diarrhea (16%), vomiting (15%), fatigue (11%), gastroesophageal reflux (7%) and constipation (6%), which were predominantly grade 1-2 in severity.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct304",{"title":223,"drug":224,"company":228,"phase":183,"disease":229,"finding":230,"url":231},"An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: Results from a Phase 1\u002F2 study",{"name":225,"slug":226,"named_as":227},"nuzefatide pevedotin","nuzefatide-pevedotin","BT5528","Bicycle Therapeutics","Nonhematologic neoplasms","The most common BT5528-related adverse events (TRAEs) were fatigue (29%), nausea (24%), diarrhea (19%), and vomiting (14%).","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct063",{"title":233,"drug":234,"company":159,"phase":183,"disease":229,"finding":237,"url":238},"First in human phase 1 study of D3S-002, a purposely designed ERK1\u002F2 inhibitor, in advanced solid tumors with MAPK pathway mutations",{"name":235,"slug":236},"D3S-002","d3s-002","D3S-002 was well tolerated, with ≥Grade 3 TRAEs observed in 18.8% (6\u002F32) of patients.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1538-7445.am2026-ct060",{"summary":240,"bullets":242},[241],"Small molecules were the most frequent modality (59% of drug-linked abstracts). PDCD1 was the most frequent target (4%). Breast cancer was the most frequent disease (12%).",[243,244,245,246,247],"AstraZeneca had the largest company share (3% of drug-linked abstracts).","Antibody-drug conjugates accounted for 12% of drug-linked abstracts.","Bispecific antibodies accounted for 8% of drug-linked abstracts.","TUBB was the next most frequent target (4%).","Non-small cell lung cancer (NSCLC) was the next most frequent disease (11%).",[],[250,251],{"name":60,"count":61,"share":62,"previous_count":159,"previous_share":159,"direction":159},{"name":67,"count":68,"share":69,"previous_count":159,"previous_share":159,"direction":159},1793970603090]